Posted by Michael Wonder on 30 Jun 2021
In revised evidence report, ICER confirms judgment that evidence is insufficient to demonstrate net health benefit of aducanumab for patients with Alzheimer’s disease
30 June 2021 - Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, the revised report finds the price range needed to reach standard cost effectiveness thresholds is $3,000-$8,400, representing an 85%-95% discount from the announced list price.
The ICER today released its revised Evidence Report assessing the comparative clinical effectiveness and value of aducanumab (Aduhelm, Biogen) for the treatment of Alzheimer’s disease.
A draft version of this report was previously open for a four-week public comment period; this updated version reflects changes made based on the breadth of the FDA label, the treatment’s announced price, and comments received from the manufacturer, patient groups, clinicians, and other stakeholders.
